Testing Herbal Supplements to USP and AOAC Standards: The Gap European Brands Discover Too Late

A European brand we spoke with last year had done everything right by EU standards. Their chamomile extract carried a full Ph.Eur. monograph test package. Heavy metals were within DGCCRF limits. Microbiological counts were clean. They submitted the dossier to a US distribution partner, who passed it to their regulatory counsel. It came back with one note: “None of this maps to 21 CFR Part 111.”

Six months of testing. Approximately €18,000 in lab costs. And they had to start over.

This isn’t an edge case. It’s the standard experience for European herbal supplement brands the first time they approach the North American market — and it’s rooted in a structural difference between how European and US/Canadian labs are built, trained, and accredited. Understanding that difference before you commission testing is the single most leveraged decision you can make in an export programme.

The European Lab Landscape Was Built for Ph.Eur., Not USP or AOAC

The European Pharmacopoeia (Ph.Eur.) is a genuinely rigorous reference. Its ~350 herbal drug monographs cover identity, purity, and assay requirements that are scientifically defensible and legally enforceable across EU member states. EDQM — the European Directorate for the Quality of Medicines — maintains these monographs with thorough revision cycles, and European contract labs have spent decades building validated capacity around Ph.Eur. methods. That investment is real and it shows.

The problem is that the US and Canada operate on a parallel system that doesn’t map neatly onto any of it. The United States Pharmacopeia (USP), AOAC International methods (the FDA-endorsed reference for analytical food and supplement testing), and the American Herbal Pharmacopoeia (AHP) form the methodological backbone of FDA’s dietary supplement programme. These aren’t interchangeable references. A Ph.Eur. identity test for Echinacea purpurea root doesn’t satisfy a USP General Chapter <563> botanical identity requirement. A heavy metals result reported against DGCCRF thresholds or Ph.Eur. limits doesn’t map to the elemental impurity framework under USP <232> and <2232>, which are dose-based, require ICP-MS with USP-specific calibration, and cover 24 elements — not the standard four that most European panels report.

When a European lab offers to run “heavy metals testing,” what they almost always mean is lead, cadmium, arsenic, and mercury against Ph.Eur. thresholds, typically by ICP-OES or atomic absorption spectroscopy. What an FDA submission requires is elemental impurities per USP <232>/<233>/<2232>: different permitted daily exposure (PDE) limits, a different list of elements, and results that require dose-per-day calculations to establish compliance. A European lab reporting mg/kg concentrations without those calculations doesn’t provide actionable data for a 21 CFR Part 111 quality dossier — even if the analytical chemistry itself is sound.

We’ve reviewed COAs from eight different European labs submitted for brands targeting the US market over the past two years. Every single one had at least one critical deficiency from an FDA perspective: a missing HPTLC fingerprint panel, microbiology reported to Ph.Eur. rather than USP <61>/<62>, heavy metals without dose-calculation, or pesticide screening against EU MRLs rather than FDA’s Pesticide Analytical Manual limits. Not because those labs are doing poor science — they’re not. But because they were designed for a different regulatory audience.

What 21 CFR Part 111 and Health Canada’s NHP Regulations Actually Require

FDA’s dietary supplement Current Good Manufacturing Practice regulation — 21 CFR Part 111 — is unambiguous on identity: every component used in production must have 100% identity verification before release into manufacturing. Not statistical sampling. Not supplier certificates of analysis reviewed in isolation. Identity testing on every incoming lot, with methods validated to detect substitution of similar species.

That has a specific practical consequence: the identity testing method must be capable of catching adulteration with botanically related species — the most common form of herbal fraud in global supply chains. A 2015 BMC Medicine study using DNA barcoding found that 59% of herbal supplement products tested failed species authentication. Adulteration is a live enforcement issue, not a theoretical concern, and FDA investigators reviewing a CGMP programme know the difference between a TLC result and a validated HPTLC fingerprint.

HPTLC — High-Performance Thin-Layer Chromatography — is referenced explicitly in the American Herbal Pharmacopoeia and aligns with USP botanical monographs. It provides resolution sufficient to distinguish between closely related species and, when run against validated reference standard libraries, produces fingerprints that are defensible under inspection. TLC, which most European labs use for routine botanical identity, is a lower-resolution technique. It passes Ph.Eur. requirements, but it doesn’t give FDA inspectors or US quality teams the confidence they’re looking for.

Health Canada’s Natural Health Products Regulations take a similar approach from a different angle. NHP licensing and site licence applications require testing documentation that follows Health Canada’s guidance documents — which reference USP, the Food Chemicals Codex (FCC), and in some cases BP monographs. As of 2025, Health Canada’s Natural Health Products Database lists over 130,000 licensed products. The overwhelming majority of botanical ingredient specifications in those filings draw on USP or FCC, not Ph.Eur. A European lab that has never prepared testing packages for a Canadian NHP application will produce documentation that doesn’t fit the template a Health Canada reviewer expects to see.

None of this is insurmountable. But brands that discover it at the submission stage — rather than at the testing design stage — face a painful and expensive rework cycle.

Four Specific Testing Gaps That Surface Most Often

Across the submissions we’ve supported, four gaps appear with enough regularity that they’re worth naming specifically.

Botanical identity by HPTLC. Ph.Eur. uses TLC for many herbal identity tests; the US market expects HPTLC with validated fingerprint comparison to authenticated reference standards. The AHP and USP maintain reference libraries for commonly traded botanicals. A European lab without access to those libraries — and without a validated HPTLC programme accredited under ISO 17025 — cannot produce the results a US quality team will accept.

Elemental impurities to USP <232>/<233>/<2232>. The oral PDE for lead under USP <232> is 5 µg/day. To calculate compliance, you need the daily dose of the finished product, not just the elemental concentration in the raw material. European labs reporting mg/kg values leave the compliance calculation undone — which means whoever is reviewing the dossier has to reconstruct it, or, more likely, flags it as deficient.

Microbiology to USP <61> and <62>. Ph.Eur. 2.6.12 and 2.6.13 are methodologically close to their USP counterparts, but not identical in media specifications or all acceptance criteria. The chapter reference on the COA matters. A US contract manufacturer or distributor building their own CGMP file will want to see “USP <61>” and “USP <62>” in print, and a Ph.Eur. reference — even if numerically compliant — creates a documentation gap they can’t easily close.

Pesticide residues against FDA and USDA limits. The EU operates on MRLs set under Regulation (EC) 396/2005 and Commission Regulation (EU) 2023/915 for contaminants in food and feed. FDA’s Pesticide Analytical Manual (PAM) and, for dietary supplements, USP <561>, establish a different analytical framework. The specific pesticide panels and detection limits don’t overlap completely. A clean European pesticide screen does not automatically mean compliance with US import requirements — particularly for botanicals sourced from regions with different agricultural chemical practices.

Each of these gaps individually adds 3–6 weeks and €2,000–8,000 in retesting costs when discovered post-submission. Combined, they can push a product launch timeline back by a full quarter and erode the commercial rationale for the distribution agreement that prompted the testing in the first place.

Bridging the Gap With a Coordinated Cross-Continental Approach

The tempting shortcut is to find a European lab that claims to “also do USP testing.” In practice, this almost always means they’ve run a handful of USP methods on an ad hoc basis, without a validated, accredited programme behind them. ISO 17025 accreditation scopes are specific and publicly verifiable — you can, and should, check whether a lab holds accreditation for the specific USP chapters you need. Ask to see the accreditation certificate and the scope document that comes with it. If USP <61>, <62>, <232>, <233>, and <561> aren’t listed by chapter number in that scope, they don’t have a validated programme. They have a workaround.

What works reliably for European brands with North American ambitions is a coordinated testing strategy across labs with the right expertise in the right jurisdictions. A European lab handles EU regulatory documentation — Ph.Eur. testing, safety assessments under EU Cosmetics Regulation 1223/2009 where applicable, REACH declarations for ingredient suppliers. An ISO 17025-accredited North American lab handles the USP/AOAC testing required for FDA dossiers and Health Canada licensing. The European regulatory framework and the North American framework both get satisfied, by labs that are actually built for each.

The coordination between those two environments is where brands lose time and money if it’s poorly managed. Transatlantic sample shipments take 7–10 business days under standard conditions. Customs documentation for botanical materials — especially raw plant material, extracts, or reference standards — requires attention to CITES regulations for certain species, phytosanitary certificates, and IATA packaging requirements for extracts that may be classified as controlled. Method alignment between two QMS environments needs someone who understands both regulatory frameworks and can ensure the lot numbers, sample descriptions, and method references are consistent across both sets of reports.

A partner-lab model — where a single advisory contact manages sampling logistics, chain of custody, report compilation, and regulatory formatting — compresses that process significantly. The final testing package that lands in front of an FDA reviewer or a Health Canada licence officer is coherent: same lot numbers, complementary methods, no conflicting data, and narrative documentation that ties the two sets of results together into a complete quality dossier.

European brands that design their testing architecture before formulation development — rather than after it — consistently get to submission faster and with fewer revision cycles. If you’re at the early evaluation stage, the first question worth asking any lab isn’t about price or turnaround time. It’s: “Can you show me your ISO 17025 accreditation scope document, and does it list these USP chapters by name?” The answer to that question is more informative than any sales conversation.

---

Written by Nour Abochama, Quality & Regulatory Advisor, Care Europe | VP Operations, Qalitex. Learn more about our team

Talk to our team about EU market entry Contact us

Related from our network

• USP and AOAC-accredited herbal supplement testing for North American submissions — Qalitex Laboratories provides ISO 17025-accredited botanical identity, elemental impurities, and dietary supplement testing to FDA and Health Canada standards.
• Natural health product testing and NHP licensing support for botanical brands entering Canada — Androxa prepares Health Canada-standard testing documentation for European brands seeking Canadian NHP site licences and product registrations.